Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian prostate cancer project study

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2027-2038

  Boccardo, Francesco ^a   Rubagotti, Alessandra ^b   Barichello, Mario ^b   Battaglia, Michele ^b   Carmignani, Giorgio ^b   Comeri, Giancarlo ^b   Conti, Giario ^b   Cruciani, Giorgio ^b   Dammino, Sandro ^b   Delliponti, Umberto ^b   Ditonno, Pasquale ^b   Ferraris, Valentino ^b   Lilliu, Sergio ^b   Montefiore, Franco ^b   Portoghese, Filippo ^b   Spano, Giovanni ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HORMONE INHIBITION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 0033026221     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2027     Document Type: Article

References (33)

1. Kirby RS: Recent advances in the medical management of prostate cancer. Br J Clin Pract 50:88-93, 1996
2. Labrie F, Dupont A, Belanger A, et al: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. J Steroid Biochem 23:833-841, 1985
3. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
4. Denis L: Role of maximal androgen blockade in advanced prostate cancer. Prostate 5:17-22, 1994 (suppl)
5. Boccardo F, Pace M, Rubagotti A, et al: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 29:1088-1093, 1993
6. Tyrrell CJ, Altwein JE, Klippel F, et al: Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer: Survival update. Cancer 72:3878-3879, 1993 (suppl 12)
7. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
8. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346:265-269, 1995
9. Brogden RN, Chrisp P: Flutamide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging 1:104-115, 1991
10. Wysowski DK, Fourcroy JL: Flutamide hepatotoxicity. J Urol 155:209-212, 1996
11. Pfitzenmeyer P, Poucher P, Piard F, et al: Nilutamide pneumonitis: A report on eight patients. Thorax 47:622-627, 1992
12. Decensi AU, Boccardo F, Guarneri G, et al: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 146:377-381, 1991
13. Sogani PC, Whitmore WF: Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Urol 122:640-645, 1979
14. Lundgren R: Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59:156-158, 1987
15. Chang A, Yeap B, Davis T, et al: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Oncol 14:2250-2257, 1996
16. Goa KL, Spencer CM: Bicalutamide in advanced prostate cancer: A review. Drugs Aging 12:401-422, 1998
17. Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47:3843, 1996
18. Kaisary AV: Current clinical studies with a new nonsteroidal anti-androgen, "Casodex." Prostate 5:27-33, 1994 (suppl)
19. Prout GR Jr. Diagnosis and staging of prostatic carcinoma. Cancer 32:1096-1103, 1973
20. Tyrrell CJ, Kaisary AV, Iversen P, et al: A randomised comparison of "Casodex"™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447-456, 1998
21. Slack NH, Brady MF, Murphy GP: A re-examination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 54:564-574, 1984
22. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. Kaisary AV, Tyrrell CJ, Beacock C, et al: A randomised comparison of monotherapy with "Casodex" 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 28:215-222, 1995
24. Chodak G, Sharifi R, Kasimis B, et al: Single agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46:849-855, 1995
25. Iversen P, Tveter K, Varenhorst E: Randomised study of "Casodex" 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 30:93-98, 1996
26. Tyrrell C: Tolerability and quality of life aspects with the anti-androgen "Casodex" (ICI 176,334) as monotherapy for prostate cancer. Eur Urol 26:15-19, 1994 (suppl 1)
27. Iversen P, Tyrrell CJ, Kaisary AV, et al: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51:389-396, 1998
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
30. Siegel S: Nonparametric Statistics for the Behavioral Sciences. Tokyo, Japan, McGraw-Hill Kogakusha, Ltd, 1956
31. Chatelain C, Fourcade RO, Delchambre J: Bicalutamide (Casodex™) versus combined androgen blockade (CAB): Open French multicentre study in patients with metastatic prostate cancer. Br J Urol 80:283, 1997 (abstr 1111; suppl 2)
32. Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71:1143-1150,1993 (suppl 3)
33. Migliari R, Muscas G, Usai E: Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol 148:338-341, 1992